Next-generation sequencing to guide cancer therapy.

Area of Science:

• Genomics
• Oncology
• Clinical Pathology

Background:

• Technological advancements have enabled high-throughput sequencing, or next-generation sequencing (NGS), for clinical use.
• Standard formalin-fixed, paraffin-embedded specimens are now viable starting materials for NGS.
• Developing protocols and knowledge bases facilitate the clinical interpretation of NGS data.

Purpose of the Study:

• To highlight the integration of next-generation sequencing into standard clinical practice.
• To underscore the importance of understanding NGS capabilities and limitations for precision medicine.
• To inform oncology providers about the evolving landscape of genomically driven care.

Main Methods:

• Utilizing standard formalin-fixed, paraffin-embedded specimens for NGS.
• Developing and refining protocols for NGS data analysis and interpretation.
• Leveraging knowledge bases for clinical decision-making.

Main Results:

• NGS can be incorporated into routine clinical pathology workflows.
• Genomic information from NGS is increasingly actionable at the point of care.
• New targeted therapies and clinical trial designs are emerging based on genetic identifiers.

Conclusions:

• Next-generation sequencing is a transformative technology in clinical oncology.
• Understanding NGS is crucial for providing precision medicine and genomically driven care.
• The accessibility of NGS is expanding due to improved methodologies and data interpretation tools.